Participated · Series A · Nov 2025

Onchilles Pharma is pioneering a new class of cancer drugs that exploit the ELANE pathway, a vulnerability tied to elevated histone H1 levels in many tumors. Its lead asset, N17350 (NEU-001), is a tumor-directed biologic shown in preclinical studies to induce rapid, selective tumor cell death and CD8+ T-cell activation across 30 cancer cell lines and 15 in-vivo models, including chemotherapy-resistant and immunologically “cold” tumors. The company has completed GMP manufacturing of more than 5,000 doses and plans to start first-in-human studies in Australia in early 2025, with U.S. enrollment expected mid-2026, aiming for clinical proof-of-concept in the second half of 2026. A second program, NEU-002, a systemic version of the therapy, is on track for development-candidate nomination in early 2026. The firm positions its ELANE-based drugs as next-generation cytotoxics that combine potent tumor killing with immune preservation and activation, potentially addressing a broad range of solid tumors. To date, Onchilles has raised $40 million in Series A financing, including the latest $25 million Series A1 tranche to fund clinical development of N17350.

Participated · Series C · Mar 2024

Brightside Health is a telemental health provider that combines proprietary AI, purpose-built technology, and a clinician network to deliver precision psychiatry, therapy, and an award-winning Crisis Care program for individuals with elevated suicide risk. Its services are available to commercially insured and cash-pay patients in all 50 states and D.C., with appointments available in 48 hours or less, and to Medicaid and Medicare beneficiaries in select states. The company has expanded payer partnerships, including CareOregon, Blue Cross and Blue Shield of Texas, and Centene, and has published close to a dozen peer-reviewed research papers. Leadership has focused on building programs for individuals with severe mental health conditions and expanding into underserved markets. Brightside reports a capital-efficient approach and says the organization is on a comfortable path to profitability. The recent strategic Series C will support growth into new markets and new offerings and deeper Medicare and Medicaid expansion. Brightside Health is a telemedicine platform offering fast access to personalized mental health treatment, expert providers, and ongoing support via video visits, unlimited messaging, and medication delivery. The company pairs clinicians with data and technology, using a proprietary machine-learning algorithm that evaluates more than 100 data points to help providers tailor treatment and enable precision psychiatry. Its care model follows evidence-based, structured protocols delivered by a network of psychiatric providers and licensed therapists, with online check-ins monitored by providers to ensure efficacy. Brightside reports that 86% of members feel better within the first 12 weeks and 71% achieve remission in that period; a recent study showed over 50% higher treatment response and remission rates than a leading U.S. health system. The company plans to use new capital to grow headcount from 57 to an expected 175 employees this year, further enhance its platform and partnerships, and expand access to more individuals. Brightside already has go-to-market partnerships with clinically-discerning national payers that open access to superior mental health care for over 30 million insurance members nationwide.

Participated · Debt Financing · Mar 2024

Founded in 2020 and led by CEO Nathan Ough, VoltaGrid is a Houston-based advanced energy management and generation company providing behind-the-meter generation, portable power, CNG fuel supply, infrastructure, and energy management services. Its customers include data centers, AI infrastructure, utilities, and industrial clients across North America and beyond. The company reports an order book of roughly 7.5 GW through 2030. VoltaGrid plans to expand deployment and strengthen supply-chain and manufacturing capabilities following its announced acquisition of Propell Energy Technology Ltd., which adds about 1,000 employees and experience in reciprocating engines and turbine technologies. The recent $1.0 billion strategic equity investment is intended to accelerate those deployments and reduce execution risk on its projects.

Led · Equity · Jul 2023

EchoNous develops Kosmos, a compact AI-guided point-of-care ultrasound system that images the heart and other body regions. Kosmos uses deep-learning algorithms to help operators acquire images, label them, and automatically calculate measurements such as ejection fraction. The company says Kosmos delivers diagnostic-quality images comparable to larger, more expensive devices, and it ranked highly for overall image quality in an independent study of five handheld ultrasound devices. EchoNous has partnered with virtual-care company 19Labs to link Kosmos to a telehealth platform, aiming to expand care to underserved communities and improve ultrasound education with real-time virtual teaching. The Redmond, Wash.–based startup raised $7M in new funding noted in an SEC filing and confirmed by a company spokesperson. Prior financings cited in the article include a $57M Series D in September 2022 and $60M raised in September 2021. EchoNous markets Kosmos, a compact, AI-guided point-of-care ultrasound system that images the heart and other body regions. Its deep-learning algorithms assist operators in collecting high-quality images, labeling them, and automatically calculating measurements such as ejection fraction. Kosmos was rated highly for overall image quality in an independent study comparing five hand-held devices. The company is also developing the Lexsa ultrasound probe, which received 510(k) clearance last year to enable nerve, lung, vascular and musculoskeletal bedside ultrasound. Recent product and partnership activity includes a deal with Samsung to pair Kosmos with a Samsung tablet. EchoNous was launched in 2015, is based in Redmond, Wash., and has about 150 employees. EchoNous develops Kosmos, an AI-guided point-of-care ultrasound (POCUS) system that provides diagnostic-quality imaging. Kosmos is a handheld POCUS device offering continuous-wave Doppler capability and enables systolic heart function assessment, features with important cardiology applications. The system is designed for AI guidance and meets HIPAA requirements for data collection, storage, and transmission. EchoNous was founded in 2016 and is led by CEO Kevin Goodwin. The company intends to accelerate the commercial launch of Kosmos using newly raised funds. It raised $60M in a financing that combines senior secured debt and equity from Kennedy Lewis Investment Management. EchoNous builds compact ultrasound devices under its Signostics business, applying artificial intelligence, including deep and machine learning, to measure bladder volume and bladder wall thickness. Its core product, Uscan, is a miniaturized AI ultrasound tool for bladder and kidney care with regulatory approvals in the U.S., Australia, Canada, Europe, Singapore and Japan, and the company exports globally. Management is led by Kevin Goodwin (CEO) and Niko Pagoulatos, PhD (COO & CIO). The company intends to use recent funding to continue market conversion of Uscan, advance a nursing tool with a vein-finding solution, and bring a major new AI-driven ultrasound project to market. EchoNous raised $35m in the reported financing, which the company will deploy against those commercial and development priorities.

Led · Equity · Jul 2022

Sanctuary Wealth, launched in 2018 and led by CEO Jim Dickson, operates a multi-custodial hybrid platform that supports advisor-owned firms. Its core offering is a platform and suite of solutions—including a bespoke alternative investments platform, a Turnkey Asset Management Program (TAMP), insurance solutions, family office services, legacy planning, lending, and an integrated technology stack—to assist partner advisory firms. The company emphasizes enabling advisors to own their businesses and values while accessing resources of a larger organization. Sanctuary has built technology integrations into a best-in-class workstation to support operations and client service. The firm currently supports 79 partner firms across 26 states with approximately $25 billion in assets under advisement. It plans to use new capital to accelerate M&A activity, drive organic growth of partner firms, and advance technology and talent-management initiatives.